journal article
Open Access
Feb 28, 2022
Future Drug Targets in Periodontal Personalised Medicine—A Narrative Review
Abstract
Periodontal disease is an infection-driven inflammatory disease characterized by the destruction of tooth-supporting tissues. The establishment of chronic inflammation will result in progressive destruction of bone and soft tissue changes. Severe periodontitis can lead to tooth loss. The disease has complex pathogenesis with an interplay between genetic, environmental, and host factors and pathogens. Effective management consists of plaque control and non-surgical interventions, along with adjuvant strategies to control inflammation and disrupt the pathogenic subgingival biofilms. Recent studies have examined novel approaches for managing periodontal diseases such as modulating microbial signaling mechanisms, tissue engineering, and molecular targeting of host inflammatory substances. Mounting evidence suggests the need to integrate omics-based approaches with traditional therapy to address the disease. This article discusses the various evolving and future drug targets, including proteomics, gene therapeutics, vaccines, and nanotechnology in personalized periodontal medicine for the effective management of periodontal diseases.
Topics
No keywords indexed for this article. Browse by subject →
References
153
[1]
Nazir "Global Prevalence of Periodontal Disease and Lack of Its Surveillance" Sci. World J. (2020) 10.1155/2020/2146160
[2]
Seymour "Drugs and the periodontium" J. Clin. Periodontol. (1988) 10.1111/j.1600-051x.1988.tb01549.x
[3]
Halawany "Is psychological stress a possible risk factor for periodontal disease? A systematic review" Afr. J. Psychiatry (2015) 10.4172/psychiatry.1000217
[4]
Kinane "Susceptibility and risk factors in periodontal disease" Ann. R. Australas. Coll. Dent. Surg. (2000)
[5]
Murakami "Dental plaque–induced gingival conditions" J. Periodontol. (2018) 10.1002/jper.17-0095
[6]
Szulc "Local drug delivery in periodontitis treatment: A review of contemporary literature" Dent. Med. Probl. (2018) 10.17219/dmp/94890
[7]
Nishihara "Microbial etiology of periodontitis" Periodontology 2000 (2004) 10.1111/j.1600-0757.2004.03671.x
[8]
Ditu, L.-M. (2017). Impact of Dental Plaque Biofilms in Periodontal Disease: Management and Future Therapy, IntechOpen. Chapter 2.
[9]
Souza "Modulation of host cell signaling pathways as a therapeutic approach in periodontal disease" J. Appl. Oral Sci. (2012) 10.1590/s1678-77572012000200002
[10]
Hajishengallis "Periodontitis: From microbial immune subversion to systemic inflammation" Nat. Rev. Immunol. (2015) 10.1038/nri3785
[11]
Mealey "Periodontal disease and diabetes. A two-way street" J. Am. Dent. Assoc. (2006) 10.14219/jada.archive.2006.0404
[12]
Young "Manipulation of immune responses to Mycobacterium bovis by vaccination with IL-2- and IL-18-secreting recombinant bacillus Calmette Guerin" Immunol. Cell Biol. (2002) 10.1046/j.1440-1711.2002.01078.x
[13]
Tsirigotis "Balanced control of both hyper and hypo-inflammatory phases as a new treatment paradigm in sepsis" J. Thorac. Dis. (2016) 10.21037/jtd.2016.03.47
[14]
Elavarasu "Host modulation by therapeutic agents" J. Pharm. Bioallied Sci. (2012) 10.4103/0975-7406.100244
[15]
Papapanou "Periodontitis: Consensus report of workgroup 2 of the 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions" J. Clin. Periodontol. (2018) 10.1111/jcpe.12946
[16]
Slots "Low-cost periodontal therapy" Periodontology 2000 (2012) 10.1111/j.1600-0757.2011.00429.x
[17]
Mahuli "Antibiotics for periodontal infections: Biological and clinical perspectives" J. Contemp. Dent. Pract. (2020) 10.5005/jp-journals-10024-2797
[18]
Krasny "Analysis of effect of non-steroidal anti-inflammatory drugs on teeth and oral tissues during orthodontic treatment. Report based on literature review" Acta Pol. Pharm. (2013)
[19]
Gulati "Host modulation therapy: An indispensable part of perioceutics" J. Indian Soc. Periodontol. (2014) 10.4103/0972-124x.134559
[20]
Ding "Celastrol, an inhibitor of heat shock protein 90β potently suppresses the expression of matrix metalloproteinases, inducible nitric oxide synthase and cyclooxygenase-2 in primary human osteoarthritic chondrocytes" Eur. J. Pharmacol. (2013) 10.1016/j.ejphar.2013.01.057
[21]
Bezerra "Selective cyclooxygenase-2 inhibition prevents alveolar bone loss in experimental periodontitis in rats" J. Periodontol. (2000) 10.1902/jop.2000.71.6.1009
[22]
Reddy "Periodontal host modulation with antiproteinase, anti-inflammatory, and bone-sparing agents. A systematic review" Ann. Periodontol. (2003) 10.1902/annals.2003.8.1.12
[23]
Holzhausen "Protective effects of etoricoxib, a selective inhibitor of cyclooxygenase-2, in experimental periodontitis in rats" J. Periodontal Res. (2005) 10.1111/j.1600-0765.2005.00787.x
[24]
Eskan "The leukocyte integrin antagonist Del-1 inhibits IL-17-mediated inflammatory bone loss" Nat. Immunol. (2012) 10.1038/ni.2260
[25]
Mazzon "Effects of etanercept, a tumour necrosis factor-alpha antagonist, in an experimental model of periodontitis in rats" Br. J. Pharmacol. (2007) 10.1038/sj.bjp.0706979
[26]
Hasturk "Proresolving nanomedicines activate bone regeneration in periodontitis" J. Dent. Res. (2015) 10.1177/0022034514557331
[27]
"Pro-resolving mediators in the regulation of periodontal disease" Mol. Asp. Med. (2017) 10.1016/j.mam.2017.04.006
[28]
Lee "Resolvin E1 Reverses Experimental Periodontitis and Dysbiosis" J. Immunol. (2016) 10.4049/jimmunol.1600859
[29]
Aboelsaad "Adjunctive treatment of chronic periodontitis with daily dietary supplementation with omega-3 Fatty acids and low-dose aspirin" J. Periodontol. (2010) 10.1902/jop.2010.090628
[30]
Chee "Omega-3 fatty acids as an adjunct for periodontal therapy-a review" Clin. Oral Investig. (2016) 10.1007/s00784-016-1750-2
[31]
Naqvi "Docosahexaenoic Acid and Periodontitis in Adults: A Randomized Controlled Trial" J. Dent. Res. (2014) 10.1177/0022034514541125
[32]
Hasturk "Resolvin E1 regulates inflammation at the cellular and tissue level and restores tissue homeostasis in vivo" J. Immunol. (2007) 10.4049/jimmunol.179.10.7021
[33]
Serhan "Resolving inflammation: Dual anti-inflammatory and pro-resolution lipid mediators" Nat. Rev. Immunol. (2008) 10.1038/nri2294
[34]
Ambili "Expression of activated transcription factor nuclear factor-kappaB in periodontally diseased tissues" J. Periodontol. (2005) 10.1902/jop.2005.76.7.1148
[35]
Spolidorio "Signaling pathways associated with the expression of inflammatory mediators activated during the course of two models of experimental periodontitis" Life Sci. (2009) 10.1016/j.lfs.2009.03.001
[36]
Balaji, T.M., Varadarajan, S., Jagannathan, R., Mahendra, J., Fageeh, H.I., Fageeh, H.N., Mushtaq, S., Baeshen, H.A., Bhandi, S., and Gupta, A.A. (2021). Melatonin as a Topical/Systemic Formulation for the Management of Periodontitis: A Systematic Review. Materials, 14.
10.3390/ma14092417
[37]
Rogers "A p38 mitogen-activated protein kinase inhibitor arrests active alveolar bone loss in a rat periodontitis model" J. Periodontol. (2007) 10.1902/jop.2007.070101
[38]
Medicherla "A selective p38 alpha mitogen-activated protein kinase inhibitor reverses cartilage and bone destruction in mice with collagen-induced arthritis" J. Pharmacol. Exp. Ther. (2006) 10.1124/jpet.105.098020
[39]
Mbalaviele "Inhibition of p38 Mitogen-Activated Protein Kinase Prevents Inflammatory Bone Destruction" J. Pharmacol. Exp. Ther. (2006) 10.1124/jpet.105.100362
[40]
Ward "SB-242235, a selective inhibitor of p38 mitogen-activated protein kinase. I: Preclinical pharmacokinetics" Xenobiotica (2002) 10.1080/00498250110100720
[41]
Chopra "Pharmacological profile of AW-814141, a novel, potent, selective and orally active inhibitor of p38 MAP kinase" Int. Immunopharmacol. (2010) 10.1016/j.intimp.2010.01.007
[42]
Ryoo "BIRB 796 has Distinctive Anti-inflammatory Effects on Different Cell Types" Immune Netw. (2013) 10.4110/in.2013.13.6.283
[43]
Ding "Drug evaluation: VX-702, a MAP kinase inhibitor for rheumatoid arthritis and acute coronary syndrome" Curr. Opin. Investig. Drugs (2006)
[44]
Duffy "The Discovery of VX-745: A Novel and Selective p38α Kinase Inhibitor" ACS Med. Chem. Lett. (2011) 10.1021/ml2001455
[45]
Assi "The specific JNK inhibitor SP600125 targets tumour necrosis factor-alpha production and epithelial cell apoptosis in acute murine colitis" Immunology (2006) 10.1111/j.1365-2567.2006.02349.x
[46]
Ohori "Identification of a selective ERK inhibitor and structural determination of the inhibitor–ERK2 complex" Biochem. Biophys. Res. Commun. (2005) 10.1016/j.bbrc.2005.08.082
[47]
McIntyre "A highly selective inhibitor of I kappa B kinase, BMS-345541, blocks both joint inflammation and destruction in collagen-induced arthritis in mice" Arthritis Rheum. (2003) 10.1002/art.11131
[48]
Rus "The role of the complement system in innate immunity" Immunol. Res. (2005) 10.1385/ir:33:2:103
[49]
Hajishengallis "Complement and periodontitis" Biochem. Pharmacol. (2010) 10.1016/j.bcp.2010.06.017
[50]
Hajishengallis "Low-Abundance Biofilm Species Orchestrates Inflammatory Periodontal Disease through the Commensal Microbiota and Complement" Cell Host Microbe (2011) 10.1016/j.chom.2011.10.006
Showing 50 of 153 references
Metrics
15
Citations
153
References
Details
- Published
- Feb 28, 2022
- Vol/Issue
- 12(3)
- Pages
- 371
- License
- View
Authors
Cite This Article
Pradeep Kumar Yadalam, V. Kalaivani, Hammam Ibrahim Fageeh, et al. (2022). Future Drug Targets in Periodontal Personalised Medicine—A Narrative Review. Journal of Personalized Medicine, 12(3), 371. https://doi.org/10.3390/jpm12030371
Related
You May Also Like
The Enhanced Permeability and Retention (EPR) Effect: The Significance of the Concept and Methods to Enhance Its Application
Jun Wu · 2021
838 citations
A Review of the Role of Artificial Intelligence in Healthcare
Ahmed Al Kuwaiti, Khalid Nazer · 2023
696 citations
Health 2050: The Realization of Personalized Medicine through Crowdsourcing, the Quantified Self, and the Participatory Biocitizen
Melanie Swan · 2012
303 citations
Building the Partners HealthCare Biobank at Partners Personalized Medicine: Informed Consent, Return of Research Results, Recruitment Lessons and Operational Considerations
Elizabeth Karlson, Natalie Boutin · 2016
181 citations
Personalized Nanomedicine: A Revolution at the Nanoscale
Cristina Fornaguera, Maria García-Celma · 2017
159 citations